Data: Toxicity, therapeutics studied
January 1st 2011Results of an in vitro study of the potentially adverse effects of different topical glaucoma medications and preservatives showed that the preservatives polyquad and sofZia had much less toxicity when used in place of benzalkonium chloride in prostaglandin analogue formulations.
Trial compares glaucoma implants
January 1st 2011A multicenter, randomized clinical trial comparing the efficacy of the Ahmed valve implant with the B?rveldt implant for treating refractory glaucoma found that 1 year after surgery, the IOP, number of glaucoma medications, and rate of failure were lower in patients who received the B?rveldt implant.
Activities turn research into treatment
December 15th 2010The Association for Research in Vision and Ophthalmology works closely with the National Alliance for Eye and Vision Research to help ensure that adequate funding is available for both basic and translational research for the National Eye Institute.
Supplement to enhance blepharospasm therapy now available by prescription only
December 14th 2010A medical food (Zytaze, OCuSOFT) designed to provide nutritional support to enhance the effectiveness of injections of onabotulinum toxin A (Botox/Botox Cosmetic, Allergan), abobotulinum toxin A (Dysport, Tercica), and rimabotulinum toxin B (Myobloc, Solstice Neurosciences) in the treatment of blepharospasm, hemifacial spasm, and cosmetic procedures now is available in pharmacies as a prescription-only supplement.
System for accelerated corneal crosslinking receives CE mark
December 14th 2010A system for performing accelerated corneal crosslinking (KXL, Avedro) has received the European Union?s (EU?s) CE mark, which certifies that the system has met the EU?s health and safety standards and opens the door to immediate commercialization across the European economic community and in other countries recognizing the CE mark.